

## ODN 24987

<b>Cat. No.:</b>	HY-150745	
<b>CAS No.:</b>	1682661-48-8	
<b>Molecular Weight:</b>	3229.6	
<b>Sequence:</b>	DNA, d(P-thio)(C-C-T-G-G-C-c7G-G-G-G)	DNA, d(P-thio)(C-C-T-G-G-C-c <sub>7</sub> G-G-G-G)
<b>Target:</b>	Toll-like Receptor (TLR)	
<b>Pathway:</b>	Immunology/Inflammation	
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 20 mg/mL (6.19 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		0.3096 mL	1.5482 mL	3.0964 mL
	5 mM		0.0619 mL	0.3096 mL	0.6193 mL
	10 mM		---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	ODN 24987 is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 can be used for research immune disorders. ODN 24987 sequence: 5'-C-C-T-G-G-C-c7G-G-G-G-3' <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	TLR9
<b>In Vitro</b>	ODN 24987 (0.1, 1 and 10 μM, 24 h) impairs efficiently TLR9-mediated release of IFN-α by PBMCs, and prevents IL-6 release by CpG-ODN-activated human B-cells <sup>[1]</sup> . ODN 24987 (0.01, 0.1, 1, 10 μM; 48 h) impairs Imiquimod-induced IL-6 release by human PBMCs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Römmler F, et al. Guanine modification of inhibitory oligonucleotides potentiates their suppressive function. J Immunol. 2013 Sep 15;191(6):3240-53.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA